Wall Street Analyst Upgrade bluebird bio Inc. [BLUE]. What else is Wall St. saying

bluebird bio Inc. [NASDAQ: BLUE] stock went on a downward path that fall over -17.24% on Wednesday, amounting to a one-week price decrease of less than -22.66%. The company report on January 18, 2023 that bluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


bluebird bio, Inc. (Nasdaq: BLUE) (“bluebird”) today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. The gross proceeds from the public offering are expected be $120 million, before deducting underwriting discounts and commissions and offering expenses payable by bluebird and assuming no exercise of the underwriters’ option to purchase additional shares of common stock. All shares in the offering are to be sold by bluebird.

Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering.

Over the last 12 months, BLUE stock dropped by -32.46%. The one-year bluebird bio Inc. stock forecast points to a potential upside of 18.95. The average equity rating for BLUE stock is currently 3.10, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $520.44 million, with 82.91 million shares outstanding and 81.96 million shares in the current float. Compared to the average trading volume of 3.48M shares, BLUE stock reached a trading volume of 9647695 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on bluebird bio Inc. [BLUE]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BLUE shares is $7.44 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BLUE stock is a recommendation set at 3.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Barclays have made an estimate for bluebird bio Inc. shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on August 05, 2022. The new note on the price target was released on August 02, 2022, representing the official price target for bluebird bio Inc. stock.

The Average True Range (ATR) for bluebird bio Inc. is set at 0.63, with the Price to Sales ratio for BLUE stock in the period of the last 12 months amounting to 102.05. The Price to Book ratio for the last quarter was 3.09, with the Price to Cash per share for the same quarter was set at 1.62.

BLUE Stock Performance Analysis:

bluebird bio Inc. [BLUE] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -22.66. With this latest performance, BLUE shares dropped by -22.56% in over the last four-week period, additionally plugging by 25.78% over the last 6 months – not to mention a drop of -32.46% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BLUE stock in for the last two-week period is set at 35.20, with the RSI for the last a single of trading hit 28.52, and the three-weeks RSI is set at 39.71 for bluebird bio Inc. [BLUE]. The present Moving Average for the last 50 days of trading for this stock 7.44, while it was recorded at 7.49 for the last single week of trading, and 5.66 for the last 200 days.

Insight into bluebird bio Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and bluebird bio Inc. [BLUE] shares currently have an operating margin of -15322.36 and a Gross Margin at -1000.66. bluebird bio Inc.’s Net Margin is presently recorded at -15364.23.

Return on Equity for this stock declined to -65.07, with Return on Assets sitting at -47.38.

bluebird bio Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.30.

BLUE Stock EPS

The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BLUE. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for bluebird bio Inc. go to 56.40%.

bluebird bio Inc. [BLUE] Insider Position Details

There are presently around $396 million, or 81.30% of BLUE stock, in the hands of institutional investors. The top three institutional holders of BLUE stocks are: STATE STREET CORP with ownership of 12,720,480, which is approximately 596.974% of the company’s market cap and around 1.20% of the total institutional ownership; BLACKROCK INC., holding 6,898,975 shares of the stock with an approximate value of $41.57 million in BLUE stocks shares; and TANG CAPITAL MANAGEMENT LLC, currently with $38.17 million in BLUE stock with ownership of nearly 7.188% of the company’s market capitalization.

Positions in bluebird bio Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 99 institutional holders increased their position in bluebird bio Inc. [NASDAQ:BLUE] by around 27,178,443 shares. Additionally, 60 investors decreased positions by around 16,486,327 shares, while 31 investors held positions by with 22,137,152 shares. The mentioned changes placed institutional holdings at 65,801,922 shares, according to the latest SEC report filing. BLUE stock had 37 new institutional investments in for a total of 5,486,650 shares, while 26 institutional investors sold positions of 4,412,076 shares during the same period.

LEAVE A REPLY

Please enter your comment!
Please enter your name here